444 related articles for article (PubMed ID: 16635306)
1. [The value of CA19-9 in diagnosing hepatocellular carcinoma and intrahepatic cholangiocarcinoma].
Chen Y; Wang ZM; Ren ZG; Le F; Zhang BH; Xia JL; Ye SL; Tang ZY
Zhonghua Gan Zang Bing Za Zhi; 2006 Apr; 14(4):299-300. PubMed ID: 16635306
[No Abstract] [Full Text] [Related]
2. Combined hepatocellular and cholangiocarcinoma: clinical features and prognostic study in a Thai population.
Chantajitr S; Wilasrusmee C; Lertsitichai P; Phromsopha N
J Hepatobiliary Pancreat Surg; 2006; 13(6):537-42. PubMed ID: 17139428
[TBL] [Abstract][Full Text] [Related]
3. [In vivo proton magnetic resonance spectroscopy of hepatocellular carcinoma and cholangiocarcinoma].
Dong AS; Tian JM; Lu JP; Zuo CJ; Wang L; Wang J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2009 Apr; 31(2):151-4. PubMed ID: 19507591
[TBL] [Abstract][Full Text] [Related]
4. Accuracy of the preoperative determination of tumor markers in the differentiation of liver mass lesions in surgical patients.
Torzilli G; Makuuchi M; Ferrero A; Takayama T; Hui AM; Abe H; Inoue K; Nakahara K
Hepatogastroenterology; 2002; 49(45):740-5. PubMed ID: 12063982
[TBL] [Abstract][Full Text] [Related]
5. Hepatobiliary tumours.
Simcock R
Practitioner; 2001 Aug; 245(1625):668-74. PubMed ID: 11524939
[No Abstract] [Full Text] [Related]
6. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
Li YG; Zhang N
Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
[TBL] [Abstract][Full Text] [Related]
7. [Evaluation of immunohistochemical markers for differential diagnosis of hepatocellular carcinoma from intrahepatic cholangiocarcinoma].
Dong H; Cong WL; Zhu ZZ; Wang B; Xian ZH; Yu H
Zhonghua Zhong Liu Za Zhi; 2008 Sep; 30(9):702-5. PubMed ID: 19173916
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic features of patients with intrahepatic cholangiocarcinoma who are seropositive for alpha-fetoprotein-L3 and those with combined hepatocellular and cholangiocarcinoma.
Okuda H; Shiratori K; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2006 May; 21(5):869-73. PubMed ID: 16704538
[TBL] [Abstract][Full Text] [Related]
9. [Combined hepatocellular carcinoma and cholangiocellular carcinoma].
Maeda Y; Nishida M; Mori N; Tamesa T; Okada T; Tangoku A; Oka M
Nihon Rinsho; 2001 Oct; 59 Suppl 6():401-5. PubMed ID: 11761981
[No Abstract] [Full Text] [Related]
10. The Das-1 immunostain is useful for discriminating metastatic colon adenocarcinoma from cholangiocarcinoma and hepatocellular carcinoma.
Zimmerman RL; Das KM; Fogt F; Burke M; Murakata LA
Oncol Rep; 2002; 9(6):1369-72. PubMed ID: 12375050
[TBL] [Abstract][Full Text] [Related]
11. Intrahepatic cholangiocarcinoma diagnosed preoperatively as hepatocellular carcinoma.
Yamamoto M; Ariizumi S; Otsubo T; Katsuragawa H; Katagiri S; Nakano M; Takasaki K
J Surg Oncol; 2004 Aug; 87(2):80-3; discussion 83-4. PubMed ID: 15282700
[TBL] [Abstract][Full Text] [Related]
12. Combined hepatocellular and cholangiocellular carcinoma.
Murakami T; Kim T; Tomoda K; Narumi Y; Sakon M; Wakasa K; Nakamura H
Radiat Med; 1997; 15(4):243-6. PubMed ID: 9311042
[TBL] [Abstract][Full Text] [Related]
13. A resected case of a small hepatocellular carcinoma developing within the bile duct.
Yasui O; Sato T; Andoh H; Kurokawa T; Watanabe D; Sageshima M; Nanjo H
J Hepatobiliary Pancreat Surg; 2004; 11(3):193-6. PubMed ID: 15235893
[TBL] [Abstract][Full Text] [Related]
14. The utility of hepatocyte paraffin 1 antibody in the immunohistological distinction of hepatocellular carcinoma from cholangiocarcinoma and metastatic carcinoma.
Shiran MS; Isa MR; Sherina MS; Rampal L; Hairuszah I; Sabariah AR
Malays J Pathol; 2006 Dec; 28(2):87-92. PubMed ID: 18376797
[TBL] [Abstract][Full Text] [Related]
15. [Cholangiocellular carcinoma associated with liver cirrhosis].
Suzuki Y; Aoyagi Y; Naitoh A; Isokawa O
Ryoikibetsu Shokogun Shirizu; 1995; (7):357-9. PubMed ID: 8749494
[No Abstract] [Full Text] [Related]
16. Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures.
Lempinen M; Isoniemi H; Mäkisalo H; Nordin A; Halme L; Arola J; Höckerstedt K; Stenman UH
J Hepatol; 2007 Nov; 47(5):677-83. PubMed ID: 17640760
[TBL] [Abstract][Full Text] [Related]
17. The utility of CA 19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis.
Patel AH; Harnois DM; Klee GG; LaRusso NF; Gores GJ
Am J Gastroenterol; 2000 Jan; 95(1):204-7. PubMed ID: 10638584
[TBL] [Abstract][Full Text] [Related]
18. Mirizzi's syndrome with a high CA19-9 level mimicking cholangiocarcinoma.
Lin CL; Changchien CS; Chen YS
Am J Gastroenterol; 1997 Dec; 92(12):2309-10. PubMed ID: 9399781
[No Abstract] [Full Text] [Related]
19. [Combined hepatocellular-cholangiocarcinoma].
Jeen YM; Jin SY
Korean J Hepatol; 2007 Dec; 13(4):571-5. PubMed ID: 18159156
[No Abstract] [Full Text] [Related]
20. MR imaging of the liver. Primary malignant neoplasms in the adult.
Buetow PC; Midkiff RB
Magn Reson Imaging Clin N Am; 1997 May; 5(2):289-318. PubMed ID: 9113676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
